4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tango Therapeutics, Inc. (TNGX) operates in the Biotechnology industry and is headquartered in Boston, United States with about 137 employees. Its market capitalization is roughly $5 billion. In the fiscal year ended 2025-12-31, TNGX reported $62M in revenue and ($102M) in net income.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Interactive charts & full statements → Open the TNGX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $62M | $42M | $36M | $25M |
| Operating Income (EBIT) | ($111M) | ($146M) | ($114M) | ($111M) |
| Net Income | ($102M) | ($130M) | ($102M) | ($108M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $54M | $3M | $5M |
| Operating Income (EBIT) | ($49M) | ($42M) | $14M | ($41M) | ($42M) |
| Net Income | ($46M) | ($39M) | $16M | ($39M) | ($40M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $399M | $316M | $403M | $436M | — |
| Total Liabilities | $52M | $117M | $150M | $187M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TNGX viewer.
About TickerBase · Data methodology & sources